Browse > Article
http://dx.doi.org/10.5478/MSL.2014.5.3.84

In Vitro Inhibitory Effect of Licoricidin on Human Cytochrome P450s  

Kim, Sunju (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
O, Heungchan (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Kim, Jeong Ah (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Lee, Seung Ho (College of Pharmacy, Yeungnam University)
Lee, Sangkyu (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Publication Information
Mass Spectrometry Letters / v.5, no.3, 2014 , pp. 84-88 More about this Journal
Abstract
Licoricidin isolated from Glycyrrhiza uralensis is known to have anticancer, anti-nephritic, anti-Helicobacter pylori, and antibacterial effects. In this study, a cocktail probe assay and liquid chromatography-tandem mass spectrometry (LC-MS/MS) were used to investigate the modulating effect of licoricidin on cytochrome P450 (CYP) enzymes in human liver microsomes. When licoricidin was incubated at $0-25{\mu}m$ with CYP probes for 60 min at $37^{\circ}C$, it showed potent inhibitory effects on CYP2B6-catalyzed bupropion hydroxylation and CYP2C9-catalyzed diclofenac 4'-hydroxylation with half maximal inhibitory concentration ($IC_{50}$) values of 3.4 and $4.0{\mu}m$, respectively. The inhibition mode of licoricidin was revealed as competitive, dose-dependent, and non-time-dependent, and following the pattern of Lineweaver-Burk plots. The inhibitory effect of licoricidin has been confirmed in human recombinant cDNA-expressed CYP2B6 and 2C9 with $IC_{50}$ values of 4.5 and $0.73{\mu}m$, respectively. In conclusion, this study has shown the potent inhibitory effect of licoricidin on CYP2B6 and CYP2C9 activity could be important for predicting potential herb-drug interactions with substrates that mainly undergo CYP2B- and CYP2C9-mediated metabolism.
Keywords
Licoricidin; LC-MRM; cytochrome P450; inhibition;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Rendic, S. Drug Metab. Rev. 2002, 34, 83.   DOI   ScienceOn
2 Guengerich, F. P.; Vaz, A. D.; Raner, G. N.; Pernecky, S. J.; Coon, M. J. Mol. Pharmacol. 1997, 51, 147.   DOI
3 Spaggiari, D.; Geiser, L.; Daali Y.; Rudaz, S. J. Pharm. Biomed. Anal. 2014, in press.
4 Messier, C., Epifano, F.; Genovese, S.; Grenier, D. Oral Dis. 2012, 18, 32.   DOI   ScienceOn
5 Park, S. Y.; Lim, S. S.; Kim, J. K.; Kang, I. J.; Kim, J. S.; Lee, C.; Kim, J.; Park, J. H. Br. J. Nutr. 2010, 104, 1272.   DOI   ScienceOn
6 Tanaka, Y.; Kikuzaki, H.; Fukuda, S.; Nakatani, N. J. Nutr. Sci. Vitaminol. 2001, 47, 270.   DOI   ScienceOn
7 Fukai, T.; Satoh, K.; Nomura, T.; Sakagami, H. Fitoterapia 2003, 74, 720.   DOI   ScienceOn
8 La, V. D.; Tanabe, S.; Bergeron, C.; Gafner, S.; Grenier, D. J. Periodontol. 2011, 82, 122.   DOI   ScienceOn
9 Song, M.; Hong, M.; Lee, M. Y.; Jee, J. G.; Lee, Y. M.; Bae, J. S.; Jeong, T. C.; Lee, S. Food Chem. Toxicol. 2013, 59, 549.   DOI   ScienceOn
10 Turpeinen, M.; Raunio, H.; Pelkonen, O. Curr. Drug Metab. 2006, 7, 705.   DOI   ScienceOn
11 Hirota, T.; Eguchi, S.; Ieiri, I. Drug Metab. Pharmacokinet. 2013, 28, 28.   DOI   ScienceOn
12 Steward, D. J.; Haining, R. L.; Henne, K. R.; Davis, G.; Rushmore, T. H.; Trager, W. F.; Rettie, A. E. Pharmacogenetics 1997, 7, 361.   DOI
13 Fukai, T.; Marumo, A.; Kaitou, K.; Kanda, T.; Terada, S.; Nomura, T. Life Sci. 2002, 71, 1449.   DOI   ScienceOn
14 Mo, S. L.; Liu, Y. H.; Duan, W.; Wei, M. Q.; Kanwar, J. R.; Zhou, S. F. Curr. Drug Metab. 2009, 10, 730.   DOI   ScienceOn